Real-time Estimate
Cboe BZX
03:25:25 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
46.86
USD
|
-1.30%
|
|
-5.43%
|
+31.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
607.7
|
464.5
|
1,340
|
984.7
|
2,377
|
3,743
|
-
|
-
|
Enterprise Value (EV)
1 |
489.3
|
293.7
|
1,006
|
650.3
|
1,818
|
3,010
|
3,207
|
3,360
|
P/E ratio
|
-12
x
|
-5.83
x
|
-10.1
x
|
-5.81
x
|
-9.64
x
|
-13.4
x
|
-12.3
x
|
-12.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
509
x
|
6,543
x
|
1,243
x
|
208
x
|
592
x
|
1,656
x
|
208
x
|
69.3
x
|
EV / Revenue
|
410
x
|
4,136
x
|
933
x
|
137
x
|
453
x
|
1,332
x
|
178
x
|
62.2
x
|
EV / EBITDA
|
-9.24
x
|
-3.97
x
|
-9.42
x
|
-3.9
x
|
-8.21
x
|
-10.2
x
|
-11.2
x
|
-12.2
x
|
EV / FCF
|
-10.4
x
|
-4.72
x
|
-11.3
x
|
-5.56
x
|
-10.6
x
|
-14.3
x
|
-14.5
x
|
-12.8
x
|
FCF Yield
|
-9.58%
|
-21.2%
|
-8.85%
|
-18%
|
-9.4%
|
-7.01%
|
-6.91%
|
-7.8%
|
Price to Book
|
5.18
x
|
2.54
x
|
3.29
x
|
3.12
x
|
4.5
x
|
5.28
x
|
5.46
x
|
7.05
x
|
Nbr of stocks (in thousands)
|
24,222
|
32,922
|
47,157
|
53,810
|
66,799
|
78,860
|
-
|
-
|
Reference price
2 |
25.09
|
14.11
|
28.41
|
18.30
|
35.58
|
47.47
|
47.47
|
47.47
|
Announcement Date
|
3/9/20
|
3/30/21
|
3/30/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.193
|
0.071
|
1.078
|
4.737
|
4.013
|
2.261
|
18
|
54.02
|
EBITDA
1 |
-52.94
|
-74
|
-106.8
|
-166.9
|
-221.5
|
-295.7
|
-286.4
|
-274.9
|
EBIT
1 |
-53.83
|
-74.95
|
-107.7
|
-167.9
|
-222.6
|
-282.4
|
-305
|
-302.1
|
Operating Margin
|
-4,512.32%
|
-105,567.61%
|
-9,990.91%
|
-3,544.06%
|
-5,547.17%
|
-12,493.3%
|
-1,694.08%
|
-559.32%
|
Earnings before Tax (EBT)
1 |
-50.42
|
-73.81
|
-107.6
|
-163.9
|
-209.3
|
-260.8
|
-287.5
|
-296
|
Net income
1 |
-50.42
|
-73.81
|
-107.6
|
-163.9
|
-214.5
|
-267.4
|
-294.2
|
-305.3
|
Net margin
|
-4,226.49%
|
-103,960.56%
|
-9,985.25%
|
-3,460.38%
|
-5,345.85%
|
-11,828.92%
|
-1,634.46%
|
-565.18%
|
EPS
2 |
-2.090
|
-2.420
|
-2.800
|
-3.150
|
-3.690
|
-3.550
|
-3.856
|
-3.809
|
Free Cash Flow
1 |
-46.87
|
-62.21
|
-89.02
|
-116.9
|
-171
|
-211
|
-221.5
|
-262
|
FCF margin
|
-3,929%
|
-87,623.94%
|
-8,258.26%
|
-2,466.98%
|
-4,261.03%
|
-9,333.27%
|
-1,230.43%
|
-485.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
3/30/21
|
3/30/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.078
|
3.131
|
0.439
|
0.458
|
0.709
|
2.679
|
0.988
|
0.346
|
-
|
0.64
|
0.4673
|
0.24
|
0.6946
|
0.148
|
0.6934
|
EBITDA
1 |
-30.65
|
-33.59
|
-42.83
|
-43.21
|
-47.28
|
-47.7
|
-
|
-
|
-62.4
|
-73.06
|
-72.88
|
-70.03
|
-70.62
|
-
|
-
|
EBIT
1 |
-30.89
|
-33.83
|
-43.04
|
-43.45
|
-47.56
|
-47.98
|
-53
|
-58.98
|
-62.66
|
-73.53
|
-68.74
|
-70.16
|
-72.14
|
-74.6
|
-77.27
|
Operating Margin
|
-2,865.31%
|
-1,080.39%
|
-9,805.24%
|
-9,487.77%
|
-6,707.48%
|
-1,790.89%
|
-5,363.87%
|
-17,045.38%
|
-
|
-11,488.91%
|
-14,711.16%
|
-29,231.28%
|
-10,386.88%
|
-50,404.28%
|
-11,144.31%
|
Earnings before Tax (EBT)
1 |
-30.79
|
-34.63
|
-42.38
|
-41.92
|
-44.99
|
-46
|
-50.98
|
-57.46
|
-55.9
|
-66.46
|
-64.11
|
-65.64
|
-67.5
|
-70.03
|
-72.71
|
Net income
1 |
-30.79
|
-34.63
|
-42.38
|
-41.92
|
-44.99
|
-46
|
-50.98
|
-57.46
|
-60.1
|
-66.93
|
-65.84
|
-67.7
|
-69.83
|
-70.03
|
-72.71
|
Net margin
|
-2,856.59%
|
-1,105.94%
|
-9,652.62%
|
-9,153.93%
|
-6,345.7%
|
-1,716.87%
|
-5,159.82%
|
-16,606.36%
|
-
|
-10,457.81%
|
-14,090.32%
|
-28,206.92%
|
-10,054.22%
|
-47,318.92%
|
-10,485.77%
|
EPS
2 |
-0.6800
|
-0.7300
|
-0.8100
|
-0.7800
|
-0.8400
|
-0.8500
|
-0.9400
|
-1.010
|
-0.9000
|
-0.9300
|
-0.8533
|
-0.8721
|
-0.8896
|
-0.9560
|
-0.9920
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/12/22
|
8/12/22
|
11/14/22
|
2/28/23
|
5/4/23
|
8/8/23
|
11/7/23
|
2/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
118
|
171
|
334
|
334
|
559
|
733
|
536
|
383
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.9
|
-62.2
|
-89
|
-117
|
-171
|
-211
|
-222
|
-262
|
ROE (net income / shareholders' equity)
|
-36.4%
|
-51.6%
|
-43%
|
-50.6%
|
-50.2%
|
-43.5%
|
-40.9%
|
-51.1%
|
ROA (Net income/ Total Assets)
|
-33.4%
|
-47%
|
-40.3%
|
-46.6%
|
-43.4%
|
-39.3%
|
-35.4%
|
-40.8%
|
Assets
1 |
150.9
|
156.9
|
267.2
|
351.6
|
493.8
|
680
|
830.6
|
748.4
|
Book Value Per Share
2 |
4.850
|
5.550
|
8.640
|
5.870
|
7.910
|
8.990
|
8.690
|
6.730
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.49
|
0.19
|
0.44
|
1.66
|
4.69
|
1
|
7.5
|
14
|
Capex / Sales
|
41.24%
|
261.97%
|
40.45%
|
34.96%
|
116.82%
|
44.23%
|
41.66%
|
25.92%
|
Announcement Date
|
3/9/20
|
3/30/21
|
3/30/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
47.47
USD Average target price
65.07
USD Spread / Average Target +37.08% Consensus |
1st Jan change
|
Capi.
|
---|
| +31.56% | 3.74B | | +51.48% | 63.85B | | -2.34% | 41.83B | | +40.01% | 40.47B | | -10.22% | 27.17B | | +13.21% | 26.52B | | -21.51% | 18.69B | | +2.71% | 12.73B | | +22.29% | 12.11B | | +27.57% | 12.07B |
Other Biotechnology & Medical Research
|